Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model-Reference-Cited by-同舟云学术

Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model

Published:2022-01-01 Issue:1 Volume:29 Page:69-81
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Kitano Daisuke¹,Migita Suguru²,Li Yuxin¹,Takahashi Rie³,Taniguchi Yoshiki³,Kurosawa Takafumi²,Sudo Mitsumasa²,Haruta Hironori²,Hiro Takafumi²,Takayama Tadateru⁴,Mitsumata Masako⁵,Matsumoto Taro⁶,Okumura Yasuo²,Hirayama Atsushi²

Affiliation:

1. Division of Advanced Cardiovascular Imaging, Department of Medicine, Nihon University School of Medicine

2. Division of Cardiology, Department of Medicine, Nihon University School of Medicine

3. Research Support Center, Research Institute of Medical Science, Nihon University School of Medicine

4. Department of General Medicine, Nihon University School of Medicine

5. Division of Pathology, Central Clinical Laboratory, Yamanashi Kosei Hospital

6. Division of Cell Regeneration and Transplantation, Department of Functional Morphology, Nihon University School of Medicine

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/29/1/29_56549/_pdf

Reference48 articles.

1. 1) Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S, Sharma Y, Malhotra S: Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol, 2009; 68: 4-13

2. 2) Harper RW: Drug-eluting coronary stents--a note of caution. Med J Aust, 2007; 186: 253-255

3. 3) Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P, Adriaenssens T, Vrolix M, Heestermans AACM, Vis MM, Tijsen JGP, van’t Hof AW, ten Berg JM, WOEST study investigators: Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013; 381: 1107-1115

4. 4) Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KAA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FWA, Gibson CM, ATLAS ACS 2–TIMI 51 Investigators: Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 366: 9-19

5. 5) Gibson CM, Pinto DS, Chi G, Arbetter D, Yee M, Mehran R, Bode C, Halperin J, Verheugt FWA, Wildgoose P, Burton P, van Eickels M, Korjian S, Daaboul Y, Jain P, Lip GYH, Cohen M, Peterson ED, Fox KAA: Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation, 2017; 135: 323-333

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitigating effect of clopidogrel and systematic management on adverse events after interventional therapy for coronary heart disease;Tropical Journal of Pharmaceutical Research;2022-04-28